Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Barinthus Biotherapeutics's Net Cash per Share or its related term are showing as below:
STU:2AB'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.53 Med: 0.68 Max: 2.47
Current: 0.57
During the past 7 years, the highest Price-to-Net-Cash Ratio of Barinthus Biotherapeutics was 2.47. The lowest was 0.53. And the median was 0.68.
STU:2AB's Price-to-Net-Cash is ranked better than 95.64% of 803
companies
in the Biotechnology industry
Industry Median: 5.29
vs STU:2AB: 0.57
Barinthus Biotherapeutics (STU:2AB) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Barinthus Biotherapeutics Net Cash per Share Related Terms
Barinthus Biotherapeutics Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics Net Cash per Share Chart
STU:2AB vs VTGN, PSTV, PVCT: Net Cash per Share Comparison
For the Biotechnology subindustry, Barinthus Biotherapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Barinthus Biotherapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Barinthus Biotherapeutics's Price-to-Net-Cash falls into.
Barinthus Biotherapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Barinthus Biotherapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Barinthus Biotherapeutics (STU:2AB) has a Net Cash per Share of €0.85 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Barinthus Biotherapeutics and its competitors. This is 25% above median its historical median of 0.68. Over the past decade, Barinthus Biotherapeutics' Net Cash per Share has ranged from 0.53 to 2.47. According to the industry distribution chart, Barinthus Biotherapeutics ranks #35 out of 803 companies in the Biotechnology industry, placing it in the top 4.4%.
Is Barinthus Biotherapeutics' Net Cash per Share too high?
Barinthus Biotherapeutics' current Net Cash per Share of €0.85 is 25% above median its 10-year median of 0.68. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 2.47. Based on the distribution chart, Barinthus Biotherapeutics ranks #35 out of 803 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Net Cash per Share compare to VTGN and PSTV?
According to the Biotechnology industry distribution chart, Barinthus Biotherapeutics ranks #35 out of 803 companies for Net Cash per Share. This places Barinthus Biotherapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Net Cash per Share is 5.29. Historically, Barinthus Biotherapeutics' own Net Cash per Share has ranged from 0.53 to 2.47 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.29, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Barinthus Biotherapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Barinthus Biotherapeutics's current Net Cash per Share is €0.85, which is 25% above median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Net Cash per Share of €0.85. The stock's GF Value™ is €0.98, compared to a current price of €0.48 — trading 50.6% below its estimated fair value. The current Net Cash per Share is €0.85, which is 25% above median its 10-year median of 0.68. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Net Cash per Share is €0.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?
Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued.
The current stock price of €0.48 is trading 50.6% below its estimated GF Value™ of €0.98.
Key valuation signals for STU:2AB:
Net Cash per Share: €0.85 (25% above median its 10-year median of 0.68)
GF Value™: €0.98 vs. price of €0.48 (50.6% below fair value)
No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score
Get the complete analysis for STU:2AB
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2AB has been successfully added to your 
